A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma

Trial Profile

A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Adenocarcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2016

At a glance

  • Drugs Simtuzumab (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 23 Oct 2014 Planned End Date changed from 1 Sep 2014 to 1 Dec 2014 according to ClinicalTrials.gov record.
    • 18 Sep 2014 Primary endpoint (Progression-free survival) has not been met.
    • 17 Sep 2014 Results published in the Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top